Cosmetic application of nervonic acid
By adding neuraminic acid to skin topical preparations, anti-glycation, energy metabolism, DNA damage repair and soothing effects are achieved, solving the problem of insufficient application of neuraminic acid in existing technologies and improving skin aging and sensitivity problems.
Patent Information
- Application Number
- CN202510991828.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2025-07-17
- Publication Date
- 2025-10-03
AI Technical Summary
Existing technologies have failed to effectively utilize the anti-glycation, energy metabolism, DNA damage repair and soothing effects of neuraminic acid in skin topicals, especially there are few studies on its anti-glycation, energy metabolism, DNA damage repair and TRPV1 inhibition effects.
Adding neuraminic acid as an active ingredient to skin topical preparations achieves anti-glycation, energy metabolism and soothing effects by inhibiting non-enzymatic glycation end products, increasing ATP content, and inhibiting human phosphorylated histones and TRPV1 receptors.
Neuroacid shows excellent anti-glycation, energy metabolism, DNA damage repair and soothing effects in skin topical preparations, improving skin aging, dullness, redness, swelling and other problems.
Smart Images

Figure BDA0005507212170000041 
Figure BDA0005507212170000131 
Figure BDA0005507212170000141
Abstract
Description
Technical Field
[0001] The present invention relates to research on the cosmetic effects of neuraminic acid, and specifically to the application of neuraminic acid in anti-glycation, energy metabolism, DNA damage repair, soothing and / or repairing effects, as well as the application of neuraminic acid in the preparation of skin topical preparations with anti-glycation, energy metabolism, DNA damage repair, soothing and / or repairing effects. Background Art
[0002] With aging, metabolism slows, life and work pressures increase, and irregular lifestyles and dietary habits contribute to the ingested sugars not being metabolized immediately, leading to their accumulation in the body. Free sugars, in the absence of enzymes, react with collagen in the dermis to form reversible primary "glycation products," which then form highly fluorescent, cross-linked, and irreversible brown non-enzymatic glycation end-products (AGEs). This entire process is known as non-enzymatic glycation (NEG). AGEs can further directly cross-link biomolecules in the body, causing functional impairment. When elastin and collagen in the skin undergo non-enzymatic glycation reactions to form AGEs, they form cross-links of collagen and elastin. As collagen cross-linking increases, collagen solubility decreases, insoluble collagen accumulates, and skin tissue permeability decreases, hindering the exchange of nutrients and metabolites between cells. Ultimately, this leads to decreased skin elasticity, sagging, and wrinkles. Furthermore, glycated collagen turns yellow and becomes brittle. Consequently, with aging, AGEs accumulate, leading to a gradual yellowing of the skin. Furthermore, activation of AGE receptors (AGERs) induces the production of large amounts of free radicals, placing a significant burden on the body's antioxidant system, further damaging skin tissue and stimulating melanin production, trapping the skin in a vicious cycle. Consequently, anti-glycation theory has become a hot topic and target in skin beauty research in recent years. Anti-glycation is closely linked not only to skin aging but also to the appearance of dark yellow skin. Currently, representative anti-glycation ingredients include aminoguanidine, carnosine, lipoic acid, niacinamide, quercetin, and curcumin. Their mechanisms of action primarily involve blocking the development and production of AGEs. Aminoguanidine is known to effectively inhibit the glycation process, while carnosine is recognized as an effective anti-glycation ingredient in the skin care field. Natural herbal anti-glycation inhibitors continue to be sought after.
[0003] Ultraviolet rays not only destroy the outermost skin cells, but also cause dermal cell necrosis and metabolic disorder. Intracellular impurities cannot be metabolized and removed, causing sun spots on the skin, loss of elasticity, premature aging, becoming sensitive, and wrinkles. Moreover, the skin is irritated and itchy after the skin damage, and scratching causes bleeding. The skin's disease resistance and resistance are weakened, and even edema and exudation form folliculitis, and the skin diseases that are difficult to cure such as furuncle. At present, the mechanism of ultraviolet rays to skin damage is known to include: oxidative stress, inflammatory reaction, apoptosis, degradation of collagen and elastin. When the skin is exposed to too much ultraviolet radiation, skin tissue cells will produce oxidative stress, generate excessive reactive oxygen species (ROS), destroy the integrity of cell membranes and the antioxidant system in cells, and further cause the formation of cell inflammation, apoptosis and tumors. Excessive ultraviolet radiation simultaneously degrades skin collagen, hyaluronic acid, and elastin, causing skin elasticity degeneration, roughness, and wrinkle formation. Therefore, the repair method after ultraviolet damage mostly starts from these mechanisms and uses substances with antioxidant, anti-inflammatory, and matrix metalloproteinase inhibition effects. For example, ash tree extract can effectively eliminate a large number of free radicals generated in human Fb cells after UVB irradiation, reduce the expression of MMP-1 mRNA and protein, and thus combat skin damage after UVB irradiation; for example, marigold flower extract contains beta-carotene, which inhibits the activity of hyaluronidase, elastase, and MMP-1, inhibiting the formation of wrinkles and thus playing a role in ultraviolet protection.
[0004] Mitochondria are essential organelles in eukaryotic cells, key components of cellular oxidative metabolism and crucial for ATP production. Known as the "energy factory of the cell," their activity directly reflects the cell's metabolic capacity. Mitochondria promote cell renewal, stimulate enhanced skin cell functionality, and increase cellular energy, thereby enhancing skin brightness and anti-aging effects. Mitochondria in epidermal cells participate in aerobic metabolism, providing energy for other physiological functions and chemical reactions in the skin cells, maintaining normal cellular function and thus maintaining their vitality. Damage or inactivity to mitochondria can lead to insufficient energy and reduced functionality in skin cells, leading to skin aging, wrinkles, and loss of radiance. Therefore, mitochondrial activity in epidermal cells is a key indicator of cell vitality.
[0005] ATP, or adenosine triphosphate, is a key molecule in cellular energy metabolism. It is the primary energy source directly available to skin cells and a key indicator of cellular health and vitality. A decrease in ATP leads to a weakening of energy metabolism, which in turn causes functional decline in the body, most notably in the appearance of aging and dull skin. Studies have found that intense UV exposure can reduce ATP production, leading to a decrease in energy metabolism and affecting the normal function of skin cells. Therefore, the increase in ATP in damaged cells can promote cellular energy metabolism, thereby facilitating the repair of skin damage caused by UV exposure.
[0006] DNA damage can be caused by a variety of factors, including ionizing radiation, chemicals, and DNA replication errors. When DNA is damaged, cells initiate a series of repair mechanisms to repair the DNA. Histone H2A.X (also known as H2AX) is a histone protein that belongs to the histone H2A family. Histones are one of the main structural proteins of chromatin, involved in regulating gene transcription and DNA packaging, and play an important role in maintaining genome stability and DNA damage repair. γH2A.X (gamma H2A.X) is a phosphorylated form of the Histone H2A.X protein, which helps cells identify and locate the site of DNA damage and recruit other repair proteins to these sites.
[0007] Sensitive skin refers specifically to a hyperreactive state of the skin under physiological or pathological conditions, primarily affecting the face. It can manifest as subjective symptoms such as burning, stinging, itching, and tightness, with or without objective signs such as erythema, telangiectasia, and desquamation. The prevalence of sensitive skin is increasing due to factors such as environmental pollution, excessive cleaning, and lifestyle stress. The skin barrier is the skin's first line of defense. Damage or dysfunction of the skin barrier can lead to increased skin sensitivity and an inflammatory response. However, sensitive skin can also manifest in cases where the skin barrier function is normal and no inflammatory response occurs. Alternatively, there is neural hyperreactivity, with receptors such as TRPs expressed on the surface of keratinocytes that sense temperature and pain. TRPV1, a polyphasic receptor widely distributed in the peripheral nervous system, can be activated directly or indirectly by various ligands. This signals are transmitted to nerve centers via electrical signals, producing symptoms such as stinging and itching. Furthermore, the calcium influx triggered by TRPV1 activation can trigger neuroinflammation, ultimately leading to symptoms such as redness and erythema. Therefore, inhibition of TRPV1 is also a key target for evaluating cosmetic raw materials with soothing effects.
[0008] Oil is one of the four essential nutrients for the human body. In addition to providing energy, some oils or fatty acids, especially some fatty acids that the human body cannot synthesize on its own, have important health and medicinal functions for maintaining normal physiological functions of the human body. Fatty acids are usually stored in the human body in the form of triglycerides, or react with glycerol to synthesize phospholipids. Cis-15-tetracosenoic acid, also known as nervonic acid (NA), is a very long chain monounsaturated fatty acid that was first isolated from shark brain tissue. In 1925, Klenk extracted a molecular formula of C from the nervous tissue of mammals. 24 H 46 Nerve acid is a long-chain monounsaturated fatty acid of ω-2, named nervonic acid. Japanese scholar Tsujimoto extracted nervonic acid from sharks in 1926 and determined its structure to be cis-form, hence its name, selacholeic acid. With a relative molecular mass of 366.6, it is an ω-9 ultra-long-chain monounsaturated fatty acid. The pure substance appears as white flaky crystals at room temperature, soluble in organic solvents but insoluble in water.
[0009]
[0010] Sharks were originally the primary source of neuraminic acid. However, to protect sharks and maintain ecological sustainability, international bans on shark hunting have significantly limited the source of neuraminic acid. With the development of oil chemistry, scientists discovered the presence of neuraminic acid in plant fruits and seeds. This shift from animal to plant sources has greatly promoted the research and development of neuraminic acid, making plant sources a key source of neuraminic acid. Currently, neuraminic acid has been found in over 30 species from 11 families and 16 genera of plants, including both woody and herbaceous plants, with the majority belonging to the Brassicaceae family (including 13 species). Rapeseed is a major oilseed crop in my country. It is high in oil, rich in unsaturated fatty acids, cold-tolerant and shade-tolerant, and highly adaptable. Rapeseed is cultivated throughout my country from north to south and from east to west. Currently, the three main types of rapeseed cultivated in my country are Brassica napus (Brassica napus), Brassica rapa (Brassica rapa), and Brassica juncea (Brassica juncea).
[0011] At present, reports on the discovery of neuraminic acid mostly focus on extraction processes, synthesis, separation and purification or toxicological data. For example, Guangzhou Chemical published "Synthesis of cis-15-tetracosenoic acid by ethylene oxide method" in the 24th issue of 2015. For another example, "Study on the toxicity of neuraminic acid (cis-15-tetracosenoic acid)" was published in the 1st issue of Chinese Journal of Geriatric Health Medicine in 2020. For another example, Chinese patent 96122232.8 discloses a method for the separation and preparation of cis-15-tetracosenoic acid (neuraminic acid). However, these reports did not mention the related efficacy of neuraminic acid, especially its application in skin topical preparations.
[0012] Chinese invention patent 201810568900.4 discloses an anti-glycation black tea extract and its preparation method, Chinese invention patent 202210159009.1 discloses the anti-glycation use and detection method of Bauhinia leucoderma extract, and Chinese invention patent 202111648102.0 discloses an anti-glycation Chinese herbal medicine extract. There are also many patent applications for anti-glycation compositions, involving bamboo lily, mangosteen, rhodiola rosea, dandelion, etc., but none of them involve the anti-glycation research of neuraminic acid.
[0013] Chinese invention patent 202011402345.1 discloses an in vitro simulation of HaCaT cell lines with high TRPV1 expression, which is believed to be applicable to a cytological method for evaluating the discomfort of sensitive skin. Chinese invention patent 202111561937.2 discloses a method for separating and purifying anoectin and its application in soothing cosmetics. It is reported that the extract can inhibit the activation of TRPV1 on human embryonic kidney cells caused by capsaicin stimulation and reduce the influx of cellular calcium ions caused by inflammatory mediators. Chinese invention application 202210359229.9 discloses a preparation method for a desalted purslane extract with TRPV1 antagonism and its application. However, none of these literature reports and patent applications involve research on the inhibitory effect of neuraminic acid on TRPV1.
[0014] Chinese Patent No. 202311048043.2 discloses that a biosynthesized royal jelly acid promotes mitochondrial ATP and NADPH synthesis in skin fibroblasts. Chinese Patent No. 201310625970.6 discloses that loquat leaves can repair UV damage and promote energy metabolism. However, these patents do not address the role of nervonic acid in promoting ATP energy metabolism.
[0015] In summary, to date, no evidence has been found that neuraminic acid has anti-glycation, energy metabolism, DNA damage repair, soothing and / or repair effects. Summary of the Invention
[0016] The present invention provides cosmetic applications of nervonic acid, wherein the cosmetic applications are selected from: anti-glycation, energy metabolism, DNA damage repair, soothing and / or repair effects.
[0017] In a preferred embodiment, the anti-glycation effect is achieved by inhibiting non-enzymatic glycation end products.
[0018] In a preferred embodiment, the energy metabolism effect is achieved by increasing ATP content.
[0019] In a preferred embodiment, the DNA damage repair effect is achieved by inhibiting human phosphorylated histones.
[0020] In a preferred embodiment, the soothing and / or repairing effect is achieved by inhibiting the capsaicin receptor TRPV1.
[0021] In a preferred embodiment, the nervonic acid is used at a concentration of at least 0.0625 mg / mL. In a preferred embodiment, the nervonic acid is used at a concentration of less than 0.5 mg / mL. In a preferred embodiment, the nervonic acid is used at a concentration of 0.125-0.5 mg / mL.
[0022] In a preferred embodiment, the concentration of nervonic acid used is 0.015625-0.0625 mg / mL.
[0023] On the other hand, the present invention also relates to the use of neuraminic acid in the preparation of a skin topical preparation having anti-glycation, energy metabolism, DNA damage repair, soothing and / or repairing effects.
[0024] In a preferred embodiment, the skin external preparation is selected from: facial cream, lotion, gel, toner, essence, facial mask, eye cream, aerosol cleansing foam, spray, shower gel, or facial cleanser. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] Figure 1 The fluorescence results of Example 3 showing changes in the content of human phosphorylated histone (γH2A.X) are shown.
[0026] Figure 2 The fluorescence results of the changes in the capsaicin receptor (TRPV1) content in Example 4 are shown. DETAILED DESCRIPTION
[0027] The present invention unexpectedly discovered that nervonic acid has excellent anti-glycation, energy metabolism, DNA damage repair, and soothing effects. Therefore, nervonic acid can be added as an effective ingredient to skin topical preparations to help improve skin dullness, redness, swelling, etc.
[0028] The purpose of the present invention is to provide the anti-glycation, energy metabolism, DNA damage repair, and soothing effects of neuraminic acid and its application in skin topical preparations.
[0029] The nervonic acid described herein may optionally be in finished packaging. In one embodiment, the packaging is a container, such as a plastic, metal, or glass tube or jar, containing the nervonic acid. The product may additionally have packaging, such as a plastic or cardboard box, for storing the container. In one embodiment, the product contains nervonic acid and has instructions for the user to apply the nervonic acid to the skin to treat signs of skin dermatitis, as discussed below. Such instructions may be printed on the container, a label insert, or any other packaging.
[0030] As used herein, "topical application" means applying or spreading directly to the external skin, scalp, or hair, for example, using the hands or an applicator such as a wipe, roller, or sprayer.
[0031] As used herein, "cosmetic" refers to cosmetic substances or preparations that maintain, restore, impart, stimulate, or enhance the physical appearance or the appearance of increased beauty or youthfulness, especially as it relates to the appearance of tissue or skin.
[0032] As used herein, "cosmetically effective amount" means an amount of a physiologically active compound or composition sufficient to treat one or more skin conditions, but low enough to avoid serious side effects. The cosmetically effective amount of a compound or composition will vary depending on the specific condition being treated, the age and physical condition of the end user, the severity of the condition being treated / prevented, the duration of the treatment, the nature of other treatments, the specific compound or product / composition employed, the specific cosmetically acceptable carrier utilized, and the like.
[0033] In order to provide a more concise description, some quantitative expressions given herein are not modified by the term "about". It should be understood that, regardless of whether the term "about" is explicitly used, each quantity given herein is intended to refer to the actual given value and also to refer to the approximate value of these given values that can be reasonably estimated by a person of ordinary skill in the art, including the approximate value of these given values caused by experimental and / or measurement conditions.
[0034] To provide a more concise description, some quantitative expressions herein are described as a range of about X amount to about Y amount. It should be understood that when a range is described, the range is not limited to the upper and lower limits described, but should include the entire range of about X amount to about Y amount or any amount therebetween.
[0035] nervonic acid
[0036] The present invention is based on the unexpected discovery that neuraminic acid has DNA damage, downregulation of γH2A.X, anti-inflammatory, and / or soothing effects. Therefore, neuraminic acid has promising applications in cosmetics as a topical skin treatment. The present invention unexpectedly discovered that neuraminic acid has excellent anti-glycation, energy metabolism, DNA damage repair, and soothing effects.
[0037] In some embodiments, neuraminic acid has anti-glycation, energy metabolism, DNA damage repair, and soothing effects, and can be added to skin topical preparations as an effective ingredient to help improve skin aging, yellowing, redness, swelling, itching, etc.
[0038] In some embodiments, nervonic acid is used at a concentration of at least about 0.0625 mg / mL. In preferred embodiments, nervonic acid is used at a concentration of less than about 0.5 mg / mL.
[0039] In some embodiments, nervonic acid is used at a concentration of about 0.125-0.5 mg / mL. In some embodiments, nervonic acid is used at a concentration of about 0.25-0.5 mg / mL.
[0040] In some embodiments, nervonic acid is used at a concentration of at least about 0.015625 mg / mL. In preferred embodiments, nervonic acid is used at a concentration of less than about 0.0625 mg / mL.
[0041] In some embodiments, nervonic acid is used at a concentration of about 0.015625-0.0625 mg / mL. In some embodiments, nervonic acid is used at a concentration of about 0.03125-0.0625 mg / mL.
[0042] Skin topical products
[0043] In some embodiments, nervonic acid can be used to prepare a topical skin preparation. The topical skin preparation is preferably a cosmetic composition, including but not limited to products in dosage forms such as creams, lotions, gels, toners, essences, facial masks, eye creams, aerosols (cleansing foams), sprays, body washes, and facial cleansers.
[0044] The term "external skin preparation" generally refers to any ingredient typically applied externally to the skin, and may include, for example, a cosmetic composition. Such cosmetic compositions may include base cosmetics, facial makeup, body makeup, hair care cosmetics, and the like. The dosage form is not particularly limited and may be selected based on the intended purpose. Depending on the dosage form and intended purpose, the cosmetic composition may also contain various cosmetically acceptable media or base excipients.
[0045] The skin topical preparation comprising nervonic acid can be topically applied to human skin and / or hair. The skin topical preparation may also include a cosmetically acceptable topical carrier, which may be from about 50 wt % to about 99.99 wt % of the skin topical preparation (e.g., from about 80 wt % to about 99 wt % of the skin topical preparation). In a preferred embodiment of the invention, the cosmetically acceptable topical carrier comprises water. The cosmetically acceptable topical carrier may comprise one or more agents selected from wetting agents, emollients, grease, wetting agents, and similar substances. In one embodiment, the cosmetically acceptable topical carrier comprises a substrate such as a nonwoven fabric or a membrane material.
[0046] Skin topical agents can be prepared into a variety of product types, including but not limited to lotions, creams, gels, sticks, sprays, ointments, cleansing liquid lotions and solid soaps, shampoos and hair conditioners, hair fixatives, pastes, foams, powders, mousses, shaving creams, wipes, patches, hydrogels, film-forming products, facial masks and skin films, films and cosmetics such as foundations and mascara. These product types can contain several types of cosmetically acceptable topical carriers, including but not limited to solutions, suspensions, emulsions (e.g., microemulsions and nanoemulsions), gels, solids and liposomes.
[0047] Skin topical preparations containing nervonic acid can be formulated as solutions. Solutions typically contain an aqueous solvent or an organic solvent (e.g., about 50% to about 99.99% or about 90% to about 99% of a cosmetically acceptable aqueous or organic solvent). Examples of suitable organic solvents include propylene glycol, polyethylene glycol, polypropylene glycol, glycerol, 1,2,4-butanetriol, sorbitol esters, 1,2,6-hexanetriol, ethanol, and mixtures thereof.
[0048] Skin topical preparations can be formulated as solutions containing emollients. Such skin topical preparations preferably contain from about 2% to about 50% of one or more emollients. As used herein, "emollient" refers to a substance used to prevent or alleviate dryness, for example, by preventing transdermal loss of skin moisture. Examples of emollients include, but are not limited to, vegetable oils, mineral oils, aliphatic esters, and the like.
[0049] Lotions can be prepared from such solutions.Lotions typically contain from about 1% to about 20% (e.g., from about 5% to about 10%) of one or more emollients and from about 50% to about 90% (e.g., from about 60% to about 80%) water.
[0050] Another type of product that can be formulated from a solution is a cream. Creams typically contain from about 5% to about 50% (e.g., from about 10% to about 20%) of one or more emollients and from about 45% to about 85% (e.g., from about 50% to about 75%) water.
[0051] Although it is preferred that the topical skin preparation containing nervonic acid contain water, the topical skin preparation can alternatively be anhydrous or an ointment that does not contain water but rather an organic and / or silicone solvent, oil, lipid, and wax. The ointment can contain a simple base of an animal or vegetable oil or a semisolid hydrocarbon. The ointment can contain from about 2% to about 10% of one or more emollients and from about 0.1% to about 2% of one or more thickeners.
[0052] The topical skin preparation can be formulated as an emulsion. If the topical carrier is an emulsion, about 1% to about 10% (e.g., about 2% to about 5%) of the topical carrier contains one or more emulsifiers. The emulsifier can be nonionic, anionic, or cationic. Examples of suitable emulsifiers include those commonly identified as suitable emulsifiers in the field of personal care and cosmetic formulations.
[0053] Lotions and creams can be formulated as emulsions. Typically, such lotions contain from 0.5% to about 5% of one or more emulsifiers. Such creams typically contain from about 1% to about 20% (e.g., from about 5% to about 10%) of one or more emollients; from about 20% to about 80% (e.g., from 30% to about 70%) of water; and from about 1% to about 10% (e.g., from about 2% to about 5%) of one or more emulsifiers.
[0054] Oil-in-water and water-in-oil single emulsion skin care preparations, such as lotions and creams, are well known in the cosmetics field and can be used in the present invention. Multiphase emulsion skin external preparations (such as water-in-oil-in-water type and oil-in-water-in-oil type) can also be used in the present invention. Generally, such single-phase emulsions or multiphase emulsions contain water, an emollient, and an emulsifier as their essential ingredients.
[0055] Skin topical preparations comprising nervonic acid can also be formulated into gels (e.g., aqueous gels, alcoholic gels, alcohol / water-based gels, or oily gels using suitable gelling agents). Suitable gelling agents for aqueous and / or alcoholic gels include, but are not limited to, natural gums, acrylic acid and acrylate polymers and copolymers, and cellulose derivatives (e.g., hydroxymethyl cellulose and hydroxypropyl cellulose). Suitable gelling agents for oils (e.g., mineral oils) include, but are not limited to, hydrogenated butylene / ethylene / styrene copolymers and hydrogenated ethylene / propylene / styrene copolymers. Such gels typically contain between about 0.1% and 5% by weight of such gelling agents.
[0056] Skin topical preparations containing nervonic acid can also be formulated as solid preparations (eg, wax-based sticks, bar soaps, powders, or wipes containing powders).
[0057] In addition to the above-mentioned components, the external preparations for skin that can be used in the present invention may contain various other oil-soluble substances and / or water-soluble substances at levels conventionally established in the technical field thereof for use in external preparations for skin and hair.
[0058] The skin topical preparation of the present invention may contain additional components commonly found in skin care compositions, such as moisturizers, skin conditioners, emulsifiers, preservatives, antioxidants, fragrances, chelating agents, etc., as long as they are physically and chemically compatible with other components in the skin topical preparation and do not affect the effects of the neuraminic acid of the present invention.
[0059] In some embodiments of the topical skin preparations of the present invention, one or more preservatives may be used. Suitable preservatives include p-hydroxyacetophenone, C1-C4 alkyl parahydroxybenzoate, and phenoxyethanol. The preservative is used in an amount of about 0.5 to about 2 weight percent, preferably about 0.5 to 1 weight percent, based on the total weight of the composition.
[0060] In one embodiment of the skin external preparation of the present invention, one or more antioxidants can be used. Suitable antioxidants include butylated hydroxytoluene (BHT), ascorbyl palmitate (BHA), butylated hydroxyanisole, phenyl-α-naphthylamine, hydroquinone, propyl gallate, nordihydroguaiaretic acid, vitamin E or a derivative of vitamin E, vitamin C and its derivatives, calcium pantothenate, green tea extract and mixed polyphenols, and mixtures of the above-mentioned substances. The antioxidant used is about 0.02 to 0.5 weight % of the total weight of the composition, and more preferably, an amount ranging from about 0.002 to 0.1 weight %.
[0061] In one embodiment of the topical skin preparation of the present invention, one or more emollients may be used. By virtue of their ability to remain on the skin surface or in the stratum corneum, they act as lubricants, thereby reducing flaking and improving the skin's appearance. Typical emollients include fatty esters, fatty alcohols, mineral oils, polyether siloxane copolymers, and the like. Suitable examples of emollients include, but are not limited to, polypropylene glycol ("PPG")-15 stearyl ether, PPG-10 cetyl ether, Steareth-10, Oleth-8, PPG-4 lauryl ether, vitamin E acetate, lanolin, cetyl alcohol, cetearyl ethylhexanoate, cetostearyl alcohol, glyceryl stearate, octyl hydroxystearate, dimethicone, and combinations thereof. Cetyl alcohol, cetearyl ethylhexanoate, cetostearyl alcohol, glyceryl stearate, and combinations thereof are preferred. When used, the emollient is used in an amount ranging from about 0.1 to about 30% by weight, preferably about 1 to about 30% by weight, based on the total weight of the composition.
[0062] In one embodiment of the topical skin preparation of the present invention, one or more moisturizers may be used. Moisturizers, also known as humectants, help enhance the effectiveness of emollients, reduce flaking, stimulate the removal of scaly skin, and improve skin feel. Polyols may be used as moisturizers, including, but not limited to, glycerin, polyalkylene glycols, alkylene polyols and their derivatives, including butylene glycol, propylene glycol, dipropylene glycol, polyglycerol, polyethylene glycol and its derivatives, sorbitol, hydroxypropyl sorbitol, hexylene glycol, 1,3-dibutylene glycol, 1,2,6-hexanetriol, ethoxylated glycerin, propoxylated glycerin, and combinations thereof. When used, the moisturizer is used in an amount of about 0.1 to about 20% by weight, preferably about 1 to about 15% by weight, based on the total weight of the composition.
[0063] In an example of the skin external preparation of the present invention, one or more emulsifiers can be used. The emulsifier can be used within the scope of an effective stabilizing amount. Preferably, based on the total weight of the composition, the emulsifier is used in an amount of about 1.0 to about 10.0 wt %, more preferably about 3.0 to about 6.0 wt %. Any emulsifier compatible with the components in the composition can be used. Suitable emulsifiers include stearic acid, cetyl alcohol, glyceryl stearate, lecithin, stearyl alcohol, Steareth-2, Steareth-20, acrylic acid (esters) / C10-30 alkyl acrylate crosspolymer, and combinations thereof.
[0064] In one embodiment of the skin external preparation of the present invention, one or more pH adjusting agents may be used. A useful pH adjusting agent in the skin external preparation of the present invention includes tromethamine. When used, the pH adjusting agent is used in an amount of about 0.1 to about 2 weight %, preferably about 0.1 to about 1 weight %, based on the total weight of the composition.
[0065] In one embodiment of the present invention, the topical preparation for skin comprises acrylates / C10-30 alkyl acrylate crosspolymer, glycerin, p-hydroxyacetophenone, glyceryl stearate and lecithin, cetearyl alcohol, cetearyl ethylhexanoate, tromethamine, or a combination thereof.
[0066] Additional cosmetic active agents
[0067] In some embodiments, the topical skin preparation may further comprise an additional cosmetic active agent. As used herein, a "cosmetic active agent" is a compound (such as a synthetic compound or a compound isolated from a natural source or natural extract) that has a cosmetic or therapeutic effect on the skin or hair, including but not limited to anti-acne agents, oil control agents, antimicrobial agents, anti-inflammatory agents, antifungal agents, antiparasitic agents, topical analgesics, sunscreens, photoprotectants, antioxidants, keratolytic agents, surfactants, moisturizers, nutrients, vitamins, energy enhancers, antiperspirants, astringents, deodorants, firming agents, anti-keratin agents, and agents for hair and / or skin conditioning.
[0068] In one embodiment, these cosmetic active agents are selected from (but are not limited to): hydroxy acids, benzoyl peroxide, D-panthenol, octyl methoxycinnamate, titanium dioxide, octyl salicylate, homosalate, avobenzone, carotenoids, free radical scavengers, spin traps, amines, retinoids such as retinol and retinyl palmitate, ceramides, polyunsaturated fatty acids, essential fatty acids, enzymes, enzyme inhibitors, minerals, hormones such as estrogen, steroids such as hydrocortisone, 2-dimethylaminoethanol, copper salts such as copper chloride, copper-containing peptides such as Cu:Gly-His-Lys, coenzyme Q10, peptides, amino acids such as proline, vitamins, lactobionic acid, acetyl-CoA, niacin, riboflavin, thiamine, ribose, electron transporters such as NADH and FADH2, and other plant extracts such as aloe vera, feverfew, oatmeal, and their derivatives and mixtures. The cosmetic active agent is typically present in an amount of from about 0.001% to about 20%, for example from about 0.005% to about 10%, such as from about 0.01% to about 5%, by weight of the topical skin preparation of the present invention.
[0069] Examples of vitamins include, but are not limited to, vitamin A, vitamin B (e.g., vitamin B3, vitamin B5, and vitamin B12), vitamin C, vitamin K, and different forms of vitamin E (e.g., α, β, γ, or Δ tocopherol), or mixtures thereof, and derivatives thereof.
[0070] Examples of hydroxy acids include, but are not limited to, glycolic acid, lactic acid, malic acid, salicylic acid, citric acid, and tartaric acid.
[0071] Examples of antioxidants include, but are not limited to, water-soluble antioxidants such as sulfhydryl compounds and their derivatives (e.g., sodium metabisulfite and N-acetylcysteine), lipoic acid and dihydrolipoic acid, resveratrol, lactoferrin, and ascorbic acid and ascorbic acid derivatives (e.g., ascorbyl palmitate and ascorbic acid polypeptide). Oil-soluble antioxidants suitable for use in the topical skin preparations of the present invention include, but are not limited to, butylated hydroxytoluene, retinoids (e.g., retinol and retinyl palmitate), tocopherols (e.g., tocopherol ethyl ester), tocotrienols, and ubiquinone. Natural extracts containing antioxidants suitable for use in the topical skin preparations of the present invention include, but are not limited to, extracts containing flavonoids and isoflavones and their derivatives (e.g., genistein and di-zein), extracts containing resveratrol, and the like. Examples of such natural extracts include grape seeds, green tea, pine bark, and propolis.
[0072] Example
[0073] The present invention will be further described below with reference to specific examples. It should be noted that the examples are intended only to further illustrate the present invention and are not to be construed as limiting the scope of the present invention. Those skilled in the art may make non-essential improvements and adjustments based on the above-described disclosure of the present invention. The test methods in the following examples, for which specific conditions are not specified, are generally based on conventional conditions or the conditions recommended by the manufacturer. Unless otherwise indicated, all percentages and parts are by weight.
[0074] Example 1: Evaluation of the anti-glycation properties of neuraminic acid
[0075] Glycation, also known as the Maillard reaction, refers to the non-enzymatic condensation reaction between carbonyl groups on reducing sugars (such as glucose) and free amino groups on macromolecules such as proteins, lipids, or nucleic acids. The covalent adducts produced by glycation reactions are collectively referred to as advanced glycation end products (AGEs). AGEs exhibit fluorescence properties, with a distinct fluorescence peak observed at 440 nm with an excitation wavelength of 370 nm. Therefore, the anti-glycation effect of a sample can be evaluated by measuring its inhibitory effect on AGEs in the glycation reaction solution.
[0076] 1.1 Experimental methods
[0077] Preparation of 2× saccharification reaction solution: Weigh 8 g of bovine serum albumin (Sigma) and 24 g of glucose (Sigma) and add 100 mL of 0.1 mol / L PBS buffer solution (Solabo) to prepare a mixed solution containing 80 mg / mL bovine serum albumin and 240 mg / mL glucose. Filter through a 0.22 μm filter membrane and set aside.
[0078] Preparation of 2× sample solutions: Prepare nervonic acid (Shaanxi Laisente Biotechnology Co., Ltd.) in PBS buffer to 0.5 mg / mL, 0.25 mg / mL, 0.125 mg / mL, 0.0625 mg / mL, and 0.03125 mg / mL solutions for later use.
[0079] Follow the steps in the table below.
[0080] Table 1
[0081] Unit (mL) A B C D 2× saccharification reaction solution 1 0 1 0 2× sample / reference solution 1 1 0 0 PBS / sample solvent 0 1 1 2
[0082] After mixing thoroughly using a vortex shaker (Shanghai Qiqian Electronic Technology, MZX-2500), the mixture was incubated in a 55°C constant-temperature incubator (Tianjin Test Instrument Co., Ltd., DH400BII) for 40–50 h. PBS or sample solvent was used in place of the sample as a negative or solvent control, 10 mg / mL aminoguanidine hydrochloride (Sigma) was used as a positive control, and PBS was used in place of the glycosylation reaction solution as a control system. After the reaction, the incubation solution was cooled to room temperature and assayed. 200 μL of the reaction solution was then added to a 96-well plate and measured using a fluorescence microplate reader (BioTek, Epoch) at an excitation wavelength of 370 nm and an emission wavelength of 440 nm. The AGE inhibition rate was calculated. Results are expressed as mean ± SD.
[0083]
[0084] Where A is the fluorescence intensity of the saccharification system of the sample group; B is the fluorescence intensity of the sample group.
[0085] A is the fluorescence intensity of PBS solution in the sample group; C is the fluorescence intensity of the saccharification system in the control group; D is the fluorescence intensity of PBS solution in the control group.
[0086] 1.2 Experimental results:
[0087] Table 2
[0088]
[0089] The AGEs inhibition experiment showed that after neuraminic acid reacted with the glycation reaction solution in the mass concentration range of 62.5μg / mL to 500μg / mL, it had the ability to inhibit the formation of AGEs compared with the control group, and P < 0.05, so neuraminic acid is considered to have anti-glycation effects.
[0090] Example 2: Changes in Adenosine Triphosphate (ATP) Content
[0091] This test evaluates the energy metabolism of a sample by stimulating fibroblasts with UVA irradiation and measuring changes in ATP levels after exposure. Fibroblasts: Batch number Fb19052002, provided by Guangdong Boxi Biotechnology Co., Ltd.
[0092] 2.1 Experimental methods
[0093] 2.1.1 Cytotoxicity assay
[0094] (1) Cell seeding: After thawing the cells, when the plating rate reaches 60%, the cells are seeded into a 96-well plate at a concentration of 8.00E+03 / well and incubated overnight in an incubator (37°C, 5% CO2).
[0095] (2) Experimental Grouping: The experiment set up a zero adjustment group, a solvent control group, a positive control group, and a neuraminic acid group. In the neuraminic acid group, each sample was set up with 8 concentration gradients, and 3 replicate wells were set up under each concentration gradient.
[0096] (3) Solution preparation: Prepare working solutions of the test substance of different concentrations according to the test concentration setting table (Table 3).
[0097] Table 3
[0098]
[0099]
[0100] (4) Administration: Administration was performed when the cell plating rate in the 96-well plate reached 50% to 60%. 200 μL of cell culture medium (Gibco) was added to each well of the solvent control group; 200 μL of culture medium containing 10% DMSO was added to each well of the positive control group; 200 μL of culture medium containing the corresponding concentration of the test substance was added to each well of the administration group; the zero-well was inoculated with no cells and only 200 μL of cell culture medium was added. After administration, the 96-well plate was placed in an incubator (37°C, 5% CO2) and cultured for 24 hours.
[0101] (5) Detection: After incubating the cells for 24 h, the supernatant was discarded and MTT working solution (0.5 mg / mL, freshly prepared, Sigma) was added. The cells were incubated at 37°C in the dark for 4 h. After the incubation period, the supernatant was discarded and 150 μL of DMSO was added to each well. The absorbance was measured at 490 nm and the cell viability was calculated. The results were expressed as mean ± SD.
[0102] (6) Calculation formula:
[0103]
[0104] 2.2 Experimental Results
[0105] Table 4
[0106] Concentration (mg / mL) Cell viability 0.0078 99.85%±4.00% 0.0156 98.70%±1.84% 0.0313 98.65%±3.65% 0.0625 97.19%±1.51% 0.125 93.78%±2.71% 0.25 93.93%±2.86% 0.5 92.83%±3.01% 1 88.82%±3.82%
[0107] The cytotoxicity test results show that when the mass concentration of neuraminic acid is 0.5 mg / mL, the cell survival rate is 92.83%. Therefore, according to the MTT results, neuraminic acid has no cytotoxicity within the concentration range of 0.5 mg / mL.
[0108] 2.3 ATP content determination
[0109] (1) Cell seeding: Resuscitate cells. When the plating rate reaches 60%, seed the cells into a 6-well plate at a concentration of 2.50E+04 cells / well and incubate in a CO2 incubator (37°C, 5% CO2) overnight.
[0110] (2) Solution preparation: divided into blank control group, negative control group, VE group (7 μg / mL) (Sigma) and neuraminic acid group (0.125 mg / mL, 0.25 mg / mL, 0.5 mg / mL).
[0111] (3) Administration: When the cell plating rate in the 6-well plate reaches 30% to 50%, the cells are divided into groups for administration, with three replicate wells per group. 2 mL of DMEM culture medium (Gibco) is added to each well of the blank control group and the negative control group, 2 mL of culture medium containing VE is added to each well of the positive control group, and 2 mL of culture medium containing the corresponding concentration of nervonic acid to be tested is added to each well of the nervonic acid group. After administration, the 6-well plate is placed in a CO2 incubator (37°C, 5% CO2) and cultured for 24 hours.
[0112] (4) UVA irradiation: Except for the blank control group, the other groups were irradiated with UVA (Philips) at a dose of 30 J / cm 2 After irradiation, the cells were placed in a CO2 incubator (37°C, 5% CO2) and cultured for 24 h.
[0113] (5) Detection: After incubation, the cells were washed twice with 2 mL / well PBS. 200 μL of lysis buffer was added to each well. The cells were lysed by pipetting and then the samples were collected. The ATP content was determined according to the instructions of the ATP kit (Biyuntian). The results were expressed as Mean ± SD.
[0114] (6) Calculation formula:
[0115]
[0116] 2.4 ATP content determination results
[0117] Table 5
[0118]
[0119] Note: When using the t-test method for statistical analysis, the significance compared with the blank control group is indicated by #; the significance compared with the negative control group is indicated by *.
[0120] Compared with the blank control group, the ATP content in the negative control group decreased from 293.39 μM / mg to 221.26 μM / mg, indicating that the stimulation conditions of this test were effective.
[0121] Compared to the negative control group, the ATP content in the positive control group (VE) increased from 221.26 μM / mg to 277.55 μM / mg, a 25.44% increase, indicating that the positive control in this test was effective. At a concentration of 0.125 mg / mL, ATP content increased from 221.26 μM / mg to 247.63 μM / mg, an 11.92% increase. At a concentration of 0.25 mg / mL, ATP content increased from 221.26 μM / mg to 253.27 μM / mg, a 14.47% increase. At a concentration of 0.5 mg / mL, ATP content increased from 221.26 μM / mg to 262.03 μM / mg, an 18.43% increase. This indicates that neuraminic acid can effectively promote energy metabolism and ATP content.
[0122] Example 3: Changes in the content of human phosphorylated histone (γH2A.X)
[0123] This test stimulates fibroblasts with UVA irradiation and measures changes in γH2A.X levels after exposure to the sample, evaluating the repairing effect of the sample. Fibroblasts: Batch number Fb19052002, provided by Guangdong Boxi Biotechnology Co., Ltd.
[0124] 3.1 Experimental methods
[0125] (1) Cell seeding: Resuscitate cells and, when the plating rate reaches 60%, seed the cells into a 24-well plate at a concentration of 2.50E+04 cells / well and incubate in a CO2 incubator (37°C, 5% CO2) overnight.
[0126] (2) Solution preparation: divided into blank control group, negative control group, TGF-β1 group (0.1 μg / mL) (Peprotech) and neuraminic acid groups (0.125 mg / mL, 0.25 mg / mL, 0.5 mg / mL).
[0127] (3) Administration: When the cell plating rate in the 24-well plate reaches 30% to 50%, the cells are divided into groups for administration, with three replicate wells per group. 1 mL of DMEM culture medium (Gibco) is added to each well of the blank control group and the negative control group, 1 mL of culture medium containing TGF-β1 is added to each well of the positive control group, and 1 mL of culture medium containing the corresponding concentration of nervonic acid to be tested is added to each well of the nervonic acid group. After administration, the 24-well plate is placed in a CO2 incubator (37°C, 5% CO2) and cultured for 24 hours.
[0128] (4) UVA irradiation: Except for the blank control group, the other groups were irradiated with UVA at a dose of 30 J / cm 2 After irradiation, the cells were placed in a CO2 incubator (37°C, 5% CO2) and cultured for 24 h.
[0129] (5) Detection: After the incubation, the DNA damage kit (Biyuntian) was used for detection (γH2A.X immunofluorescence assay) according to the instructions. The results were expressed as Mean ± SD.
[0130] (6) Calculation formula:
[0131]
[0132] 3.2 Experimental Results
[0133] The results are as follows Figure 1 and as shown in Table 6.
[0134] Table 6
[0135]
[0136] Compared with the blank control group, the γH2A.X content in the negative control group increased from 1.00 to 3.84, indicating that the stimulation conditions of this test were effective.
[0137] Compared with the negative control group, the γH2A.X level in the positive control group (TGF-β1) decreased from 3.84 to 1.09, with an inhibition rate of 71.61%, demonstrating the effectiveness of the positive control in this test. At a concentration of 0.125 mg / mL, γH2A.X decreased from 3.84 to 2.58, with an inhibition rate of 32.81%; at a concentration of 0.25 mg / mL, γH2A.X decreased from 3.84 to 1.92, with an inhibition rate of 50.00%; and at a concentration of 0.5 mg / mL, γH2A.X decreased from 3.84 to 1.41, with an inhibition rate of 63.28%. This suggests that neuraminic acid can effectively reduce γH2A.X levels and has a role in DNA damage repair.
[0138] Example 4: Changes in Capsaicin Receptor (TRPV1) Content
[0139] Capsaicin (CAP) was used to stimulate keratinocytes. Changes in capsaicin receptor (TRPV1) expression were measured to evaluate the soothing efficacy of the test sample. Keratinocytes: Ep240109, provided by Guangdong Boxi Biotechnology Co., Ltd.
[0140] 4.1 Experimental methods
[0141] 4.1.1 Cytotoxicity assay
[0142] (1) Cell seeding: After thawing the cells, when the plating rate reaches 60%, the cells are seeded into 96-well plates at a concentration of 1.00E+04 / well and incubated overnight in an incubator (37°C, 5% CO2).
[0143] (2) Experimental Grouping: The experiment set up a zero adjustment group, a solvent control group, a positive control group, and a neuraminic acid group. In the neuraminic acid group, each sample was set up with 8 concentration gradients, and 3 replicate wells were set up under each concentration gradient.
[0144] (3) Solution preparation: Prepare working solutions of the test substance of different concentrations according to the test concentration setting table (Table 7).
[0145] Table 7
[0146]
[0147] (4) Administration: Administration was performed when the cell plating rate in the 96-well plate reached 50% to 60%. 200 μL of DMEM culture medium (Gibco) was added to each well of the solvent control group; 200 μL of culture medium containing 10% DMSO was added to each well of the positive control group; 200 μL of culture medium containing the corresponding concentration of the test substance was added to each well of the administration group; zero wells were inoculated with no cells and only 200 μL of cell culture medium was added. After administration, the 96-well plate was placed in an incubator (37°C, 5% CO2) and cultured for 24 hours.
[0148] (5) Detection: After incubating the cells for 24 h, the supernatant was discarded and MTT working solution (0.5 mg / mL, freshly prepared, Sigma) was added. The cells were incubated at 37°C in the dark for 4 h. After the incubation period, the supernatant was discarded and 150 μL of DMSO was added to each well. The absorbance was measured at 490 nm and the cell viability was calculated. The results were expressed as mean ± SD.
[0149] (6) Calculation formula:
[0150]
[0151] 4.2 Experimental Results
[0152] Table 8
[0153]
[0154]
[0155] The cytotoxicity test results show that when the mass concentration of neuraminic acid is 0.0625 mg / mL, the cell survival rate is 90.28%. Therefore, according to the MTT results, neuraminic acid has no cytotoxicity within the concentration range of 0.0625 mg / mL.
[0156] 4.3 Experimental methods
[0157] (1) Cell seeding: The cells were revived and, when the plating rate reached 60%, were seeded into 24-well plates at a concentration of 5.40E+04 cells / well and incubated overnight in a CO2 incubator (37°C, 5% CO2).
[0158] (2) Solution preparation: divided into blank control group, negative control group, trans-4-tert-butylcyclohexanol group (15.6 μg / mL) (Tessin), and neuraminic acid groups (0.015625 mg / mL, 0.03125 mg / mL, 0.0625 mg / mL).
[0159] (3) Administration: When the cell plating rate in the 24-well plate reaches 50% to 60%, the cells are divided into groups for administration, with three replicate wells in each group. 1 mL of culture medium was added to each well of the blank control group, 1 mL of culture medium containing CAP (Vokay) was added to each well of the negative control group, 1 mL of culture medium containing trans-4-tert-butylcyclohexanol was added to each well of the positive control group, and 1 mL of culture medium containing neuraminic acid and CAP at the corresponding test concentrations was added to each well of the neuraminic acid group. After administration, the 24-well plate was placed in a CO2 incubator (37°C, 5% CO2) and cultured for 24 hours. TRPV1 antibody (Abcam, ab3487) was used.
[0160] (4) Detection: After incubation, the cells were fixed with 4% paraformaldehyde (Biosharp) for 30 min and immunofluorescence assay was performed. The results were expressed as Mean ± SD. The cells were photographed under a microscope (BX43, Olympus) at 20x magnification, and the images were collected and analyzed.
[0161] (5) Calculation formula:
[0162]
[0163] 4.4 Experimental Results
[0164] The results are as follows Figure 2 and as shown in Table 9.
[0165] Table 9
[0166]
[0167]
[0168] Compared with the blank control group, the TRPV1 content in the negative control group increased from 1.00 to 2.93, indicating that the stimulation conditions of this test were effective.
[0169] Compared to the negative control group, the TRPV1 level in the positive control group (trans-4-tert-butylcyclohexanol) decreased from 2.93 to 1.19, with an inhibition rate of 59.39%, indicating that the positive control in this test was effective. At a concentration of 0.015625 mg / mL, TRPV1 levels decreased from 2.93 to 2.35, with an inhibition rate of 19.80%; at a concentration of 0.03125 mg / mL, TRPV1 levels decreased from 2.93 to 2.29, with an inhibition rate of 21.84%; and at a concentration of 0.0625 mg / mL, TRPV1 levels decreased from 2.93 to 1.93, with an inhibition rate of 34.14%. This indicates that neuraminic acid can effectively reduce TRPV1 levels and has a soothing effect.
[0170] The nervonic acid described in the present invention can be used as an effective additive in the preparation of cosmetics. The skin topical preparation is preferably a cosmetic composition, including but not limited to the preparation of products in the form of creams, lotions, gels, toners, essences, facial masks, eye creams, aerosols (cleansing bubbles), sprays, shower gels and facial cleansers. The weight percentage of nervonic acid in the skin topical preparation is 0.00156%-10% (w / w). The preferred weight percentage is 0.0001%-20% (w / w). The preferred weight percentage is 0.001%-10% (w / w). The more preferred weight percentage is 0.001%-5% (w / w). The most preferred weight percentage is 0.01%-5% (w / w). In some embodiments, the weight percentage of nervonic acid in the skin topical preparation is 0.03125%-5% (w / w). The more preferred weight percentage is 0.00625%-1% (w / w). The most preferred weight percentage is 0.00625%-0.05% (w / w).
[0171] The following are specific application examples of nervonic acid in skin topical preparations, as well as the formulations and preparation methods of these dosage forms. Specific application examples are as follows: Application Example 1: Preparation of facial cream
[0172]
[0173] Application Example 2: Preparation of Emulsion
[0174]
[0175]
[0176] Application Example 3: Preparation of Gel
[0177]
[0178] Application Example 4: Preparation of Toner
[0179]
[0180] Application Example 5: Preparation of Essence
[0181]
[0182]
[0183] Application Example 6: Preparation of facial mask
[0184]
[0185] Application Example 7: Preparation of Eye Cream
[0186]
[0187]
[0188] Application Example 8: Preparation of Aerosol (Cleaning Bubble)
[0189]
[0190] Application Example 9: Spray Preparation
[0191]
[0192]
[0193] Application Example 10: Preparation of Shower Gel
[0194]
[0195] Application Example 11: Preparation of Facial Cleanser
[0196]
Claims
1. The cosmetic application of neuraminic acid, wherein the cosmetic application is selected from: anti-glycation, energy metabolism, DNA damage repair, soothing and / or repair effects.
2. The use according to claim 1, characterized in that The anti-glycation effect is achieved by inhibiting non-enzymatic glycation end products.
3. The use according to claim 1, characterized in that The energy metabolism effect is achieved by increasing ATP content.
4. The use according to claim 1, wherein The DNA damage repair effect is achieved by inhibiting human phosphorylated histones.
5. The use according to claim 1, characterized in that The soothing and / or repairing effects are achieved by inhibiting the capsaicin receptor TRPV1.
6. The use according to claim 1, wherein The concentration of the nervonic acid used is at least 0.0625 mg / mL.
7. The use according to claim 1, wherein The concentration of the nervonic acid used is below 0.5 mg / mL.
8. The use according to claim 1, wherein The concentration of the nervonic acid used is 0.125-0.5 mg / mL.
9. The use according to claim 1, wherein The concentration of the nervonic acid used is 0.015625-0.0625 mg / mL.
10. Use of neuraminic acid in the preparation of a skin topical preparation having anti-glycation, energy metabolism, DNA damage repair, soothing and / or repairing effects.
11. The use according to claim 10, characterized in that The skin external preparation is selected from: facial cream, lotion, gel, toner, essence, facial mask, eye cream, aerosol cleansing foam, spray, shower gel, or facial cleanser.
Citation Information
Patent Citations
Chinese herbal medicine for repairing ultraviolet damages and promoting energy metabolism and application of Chinese herbal medicine in cosmetics
CN104666145A
Method for separation and preparation of nervonic acid
CN1050117C
Anti-glycation black tea extract and preparation method thereof
CN108812948A
Cytological method for evaluating discomfort of sensitive skin
CN112626163A
Anti-saccharification traditional Chinese medicine extract
CN114392323A
Cited By
Preparation method of acer truncatum seed oil
CN121182549A
